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Choroideremia (CHM) is an X-linked recessive eye disease that results from mutations involving the 
Rab escort protein-1 (REP-1) gene. In 18 patients deletions of different sizes have been found. Two 
females suffering from CHM were reported to have translocations that disrupt the REP-1 gene. In 22 
patients, small mutations have been identified* Interestingly, these are all nonsense, frameshift or 
splice-site mutations; with one possible exception, missense mutations have not been found. This 
comprises all the known mutations in the disease. Hum Mutat 9:110—117, 1997.
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key w o r d s : c h o r o id e r e m ia  (CHM), m u ta t io n s ,  ra b  e s c o r t  p r o t e in - 1 (REP-1)
gene by X-autosomal translocations (Kaplan et ab,
1989; Siu et al., 1990). In these cases, X-inacti-
vation is nonrandom; the normal X is preferen­
tially inactivated, while both translocation frag­
ments remain active.
The gene for CHM was localized to the X q l3 -  
q22 region by linkage analysis (Lewis et a l., 1985; 
Nussbaum et alM 1985; Lesko et al., 1987; Sankila 
et al., 1989). This assignment was further refined
by the characterization of cytogenetically visible 
deletions in patients with CHM, mental retarda- 
tion(MR), and deafness type 3 (DFN3) (Rosenberg 
et al.} 1987; Schwartz et al., 1988; Cremers et alM 
1989a). Molecular analysis of deletions in patients 
with classic CHM (Cremers et al., 1987, 1989b, 
1990a,b) formed the basis for the positional cloning 
of a part of the CHM gene from Xq21.2 (Cremers
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INTRODUCTION
Choroideremia (CHM) is an X-linked recessive 
eye disorder characterized by progressive degener­
ation of the choroid, retinal pigment epithelium
(RPE), and retina (Goedbloed, 1942; Waarden- 
burg, 1942). Its incidence is estimated as 1 in 
100,000. The clinical manifestation of CHM
shows considerable interfamilial as well as intrafa- 
milial variability. Usually, affected males develop 
night-blindness in their teenage years, followed by 
progressive constriction of visual fields and com­
plete blindness by middle age. Female carriers gen­
erally show no serious visual impairment, but they 
have patchy pigmentation and degeneration of the 
RPE suggesting clonal areas of disease attributable 
to random X-inactivation (Heckenlively and Bird, 
1988). Occasionally, female carriers show clinical 
signs of CHM that can be ascribed to skewed X-in- 
activation (Fraser and Friedmann, 1968; Harris 
and Miller, 1968). Manifestation of the disease in 
females can also result from disruption of the CHM
© 1997 WILEY-LISS, INC
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et al., 1990c; Merry et al., 1992). Only recently,
the complete protein coding region of the gene has 
been isolated (van Bokhoven et al., 1994b)*
STRUCTURE AND FUNCTION OF THE 
CHM/REP1 GENE
The CHM mRNA has a length of approxi­
mately 5.6 kb and is expressed in various tissue 
types, including retina, choroid, and/or RPE (Cre­
mers e ta l., 1990c, unpublished observations). The 
open reading frame (ORF) is composed of 15 ex­
ons, which span a genomic sequence of at least 150 
kb. The exons range in size from 64 nucleotides to
3.4 kb and encode a protein of 653 amino acids 
(van Bokhoven et aL, 1994b).
Insight into the function of the CHM protein 
came with the biochemical purification of Rab ge- 
ranylgeranyl transferase (Rab GGTase) from rat 
brain. This multisubunit enzyme attaches gera- 
nylgeranyl (GG) groups to Rab proteins, a modi­
fication essential for their action in intracellular 
vesicular transport, Rab GGTase consists of a cat­
alytic a/p  heterodimer and an accessory compo­
nent, the Rab escort protein (REP). Molecular 
cloning of rat REP-1 revealed identity with the 
protein encoded by the CHM gene (Seabra et al.,
1992a,b, 1993; Andres e ta l., 1993). REP-1 binds
to newly synthesized Rab proteins, presents them 
to the catalytic part of the enzyme, and delivers 
the prenylated Rabs to their target membranes
(Andres et a l., 1993; Alexandrov et al., 1994).
In yeast, both the a/(S catalytic component of 
Rab GGTase (encoded by the BET4 and BET2 
genes) and REP (encoded by the MRS6/MSI4 gene) 
are essential for cell viability (Waldherretal., 1993;
Jiang et al., 1993, 1994; Benito-Moreno et a l ,  
1994; Fujimura et al., 1994; RagninietaL, 1994).
A complete loss of REP activity would likely be 
lethal in humans too. Lymphoblasts of CHM pa­
tients have a markedly decreased but still detectable
Rab GGTase activity (Seabra et al., 1993), sug­
gesting that there is compensation for the defi­
ciency of REP-1. Indeed, an autosomal homologue 
of the REP-1 gene has been identified that was 
designated CHML for choroideremia-like. The 
gene is located in lq42-qter and, like the REP-I 
gene, is expressed in a wide variety of tissues (Cre-
mersetal., 1992; van Bokhoven etal., 1994c). The 
CHML protein, or REP-2, was demonstrated to 
perform a function similar to that of REP-1. It was 
therefore hypothesized that REP-2 substitutes for 
the loss of REP-1 activity in choroideremia pa­
tients, thereby preventing symptoms in tissues and
organs other than the eye (Cremers et al., 1994)*
The apparent insufficient compensation in the eye 
might be due to the presence o f a Rab or Rabs that 
depend preferentially on REP-1 for geranylgerany- 
lation. Recently, Seabra et al. (1995) identified an 
unprenylated Rab protein in lymphoblasts from 
CHM patients that was prenylated more efficiently
by REP-1 than by REP-2. This protein, Ram/ 
Rab27, is also present at high levels in the RPE and 
choriocapillaris, suggesting that CHM  may result 
from the deficient geranylgeranylation of Ram/ 
Rab27 or a closely related protein.
HEP-1 GENE DEFECTS 
Deletions
About one-fourth of European patients with 
classic choroideremia have large deletions that in­
volve the REP-J gene.1 By contrast, no deletions 
have been found in the North American popula­
tion yet (Merry et a l., 1992). The size of the de­
letions varies widely and ranges from a few kilo- 
bases removing a single exon, to 5 -1 5  Mb 
spanning the complete REP-1 gene (Fig. 1). Only 
3 out of 18 deletions are located entirely within the 
REP-1 gene, while the others have at least one 
endpoint outside the gene. Deletion breakpoints 
show a random distribution except for 5 deletions 
that all end distally between exon 1 and p]7.6B. 
These clustered endpoints have not been charac­
terized in detail and the physical size of the chro­
mosomal segment between exon 1 and pJ7«6B is 
not known. Apart from this region there are no 
obvious hotspots for the induction of chromosomal 
breakpoints near or within the REP-1 gene.
Translocations
X-autosome translocations that involve the 
REP-1 gene have been reported in two females 
suffering from choroideremia. One female carried 
an (X;13)(q21.2;pl2) translocation and the other 
an (X;7)(q21.2;pl2) translocation. Both females 
also showed ovarian dysgenesis, a common feature 
in X-autosomal translocations involving the prox­
imal part of Xq (Teboul e ta l.,  1989). TheX-chro- 
mosomal breakpoint of the X; 13 translocatton was 
mapped to REP-J intron 12 (Cremers et al., 
1990c). The X;7 translocation breakpoint is lo­
cated either in intron 3 or in exon 4 of the REP-1 
gene (van Bokhoven et al., 1994b) (Fig. 1).
1This is based on the preliminary outcome of REP-1 mutation 
screening in a large group of unrelated CHM patients. In 39 of these 
patients, the entire REP-1 protein coding has been screened: 10 
patients have deletions, 16 patients have subtle mutations, and in the 
remaining 13 patients no mutations have been identified.
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f ig u r e  î. Deletions and translocations involving the REP-1 
gene. Adapted from van Bokhoven et ah (1994a) by permis­
sion of Oxford University Press. Asterisks mark deletions 
that have not been described previously. UH and MS are 
numbered 1 and 6, respectively, in the study by Schwartz et 
al (1993). Shaded areas indicate chromosomal regions 
which are present in the patient’s DNA. The translocation 
breakpoints were mapped using humair.hamster hybrid cell 
lines. (References for the deletions and translocations:
Point Mutations and Small Insertions/Deletions
Nucleotide substitutions and small insertions/ 
deletions that have been reported in the REP-1
LGL2905, C3: Cremers et al., 1990b; van Bokhoven et 
al., 1994a; MBU, LUN1, LUN3: van Bokhoven et al., 1994a; 
3.5, 25.6, 7.6, LGL1134, 33.1, LGL1101: Cremers et al., 
1990b, 1990c; van Bokhoven et al., 1994a; C759, 2082: Cre­
mers and Ropers, 1994; van Bokhoven et al., 1994a; MS, 
UH: Schwartz et al., 1993; van Bokhoven et aL, 1994a; 1167, 
2700,15.4: This study; t(X; 13): Cremers et al., 1989b, 1990c; 
t(X;7): Philippe et ai., 1993; van Bokhoven et al., 1994b).
gene to date are listed in Table 1. These mutations 
were identified by single strand conformation anal­
yses and heteroduplex analyses of the protein cod­
ing region of the REP-J gene*
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TABLE î. Nucleotide Substitutions and Small Insertions/Deletions in the REP-1 Gene
Patient code Position® Mutation Effect References
Nonsense mutations
1165 Exon 6 829 C->T Arg267Stop This study
LN Exon 7 907 C—>T Arg293Stop Van Bokhoven et al.» 1994a
P20.854 Exon 8 1030 C-»T Gln334Stop This study
2084 Exon 11 1388-1389 CC-^G Ser453Stop Van den Hurk et al., 1992
2.1 Exon 12 1501 G-*T Glu491Stop Van den Hurk et a!., 1992
17.1
1
Exon 12 1514 C—>A Ser495Stop Van den Hurk et al., 1992
TN Exon 12 1527 C—>A Cys499Stop Schwartz et al., 1993
Frameshift mutations
FK Exon 5 555-556 delAG Frameshift Van Bokhoven et al.» 1994a
BO Exon 5 610 insA Frameshift Van Bokhoven et al., 1994a
P23.807 Exon 6 779 delA Frameshift This study
JS Exon 8 1183 insC Frameshift Van Bokhoven et al., 1994a
1.2 Exon 12 1476 delA Frameshift Van den Hurk et aL, 1992
2086; H; JWb
A
Exon 13 1614-1617 delTGTT Frameshift Van den Hurk et al.t 1992; 
Pascal et al., 1993; 
Schwartz et al., 1993
CN Exon 14 1680-1681 deITT Frameshift Schwartz et al., 1993
Splice site mutations
P21.551 Intron 9 1274 + 1 G->A 5' splice signal This study
P21.420 Intron 10 1379 + 2 insGGT Aberrant splicing This study
M Exon 11 1442 A—>T 5' splice signal; Donnelly et al., 1994
FCb
Gln471Leuc
Intron 12 1541 -  2 A~»G Aberrant splicing Schwartz et al., 1993
CHM*Sal Intron 13 1639 + 2 insT Aberrant splicing Sankila et al., 1992
10.1 Intron 14 1801-1 G—>A 3' splice signal This study
*The nucleotide positions correspond to the sequence published by Van Bokhoven et al, (1994b). The proposed nomenclature of Beaudet 
and Tsui (1993) is used for mutations in intron sequences.
bPatients CN, TN, FC, and JW are numbered 2, 3, 4, and 5, respectively, in the study by Schwartz et al. (1993). 
cSee text.
Nonsense Mutations and Frameshift Mutations
So far, seven nonsense mutations have been de­
tected in the REP-1 gene. In addition, seven dif­
ferent deletions and insertions were identified that 
result in translational frameshifts and premature 
termination codons (Table 1). One frameshift mu­
tation, a deletion of the tetranucleotide TGTT in 
exon 13, was found in three apparently unrelated 
patients from Germany, France, and Denmark. It 
is of note that in the normal REP-1 gene the 
TGTT tetranucleotide is duplicated, which may 
render this sequence particularly susceptible to mu­
tation (e.g., by polymerase slippage during repli­
cation).
Splice Site Mutations
Included in Table 1 are six mutations that affect 
splice sites. Patient P21.420 has a 3-bp insertion at 
the 5' splice site Ln intron 10, Reverse transcriptase 
PCR (RT-PCR) analysis (Fig. 2: primers 5 and 6) 
showed that in about 80% of the patient’s REP-1 
mRNA exon 10 is absent, while the remaining 20% 
lacks exons 10 and 11. Skipping of exon 10 main­
tains the reading frame* but deletion of exons 10 
and 11 causes a frameshift resulting in a premature
termination codon (T .J.R .v.d.PoI and J.A.J.M.
v.d.Hurk, unpublished observations).
Patient FC carries an acceptor splice site muta­
tion in intron 12* RT-PCR analysis (Fig. 2: prim­
ers A  and B) revealed that this mutation results in 
deletion of exon 13 from the REP-i transcript 
thereby introducing an inappropriate stop codon at 
the border of exons 12 and 14 (M. Schwartz, un­
published observations).
The single nucleotide insertion into the donor 
splice site in intron 13 in a large family from the 
Salla region of Northern Finland (CHM*Sal) leads 
to two aberrantly spliced mRNAs. One mRNA  
results from the use o f a cryptic splice site down­
stream of the altered splice site and the other from 
the skipping of exon 13, Both m RNA products 
contain premature termination codons (Sankila et
a l ,  1992).
In patient P21.551 a mutation was identified 
that alters a strictly conserved nucleotide of the 
splice site donor sequence (Mount, 1982; Ohshima 
and Gotoh, 1987) in intron 9. Patient 10.1 carries
a mutation in the invariant A G  dinucleotide of the 
acceptor splice site in intron 14* N o formal proof 
that these mutations cause abnormal splicing has 
been obtained.
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GTCACTTCAGCACCATTTAC; primer 3: GATC-CAGAG- 
AATGCGCTAG; primer 4: TGGGGGTTAATTTTTGAGTC; 
primer 5: GATATGAAGAGATCACATTTT; primer 6: CT- 
GATTCTAAATCTTCTCTTGC; primer 7: GCAGATCTCCA- 
GGGCAGTG; primer 8: GGGTATCCAGTTTGGTGTATA)
In family M, an A-*T change at position 1442
in exon 11 predicts the substitution of a leucine for 
a glutamine and was therefore reported as a possi­
bly causative missense mutation (Donnelly et alM
1994). However, this nucleotide alteration also af­
fects the 5' splice junction in exon 11. The simi­
larity to the consensus sequence is reduced from 
86% for the authentic splice site (AG/gtaaat) to 
78% for the mutated splice site (TG/gtaaat) (ac­
cording to Shapiro and Senepathy, 1987). 
Whether this actually results in splicing artifacts 
has not been studied.
Van Bokhoven et al. (1994a) reported another 
potential splice acceptor mutation, a T“>G change 
at position —14 in intron 4, in patient PU. How­
ever, RT-PCR analysis (Fig. 2: primers C and D) 
showed that this substitution does not affect REP- 1 
RNA processing (M. Schwartz, unpublished obser­
vations).
POLYMORPHISMS
Table 2 lists the known polymorphisms in the 
REP-1 gene. The two intragenic highly polymor­
phic microsatellite markers have a combined het­
erozygosity index of 0.96.
DISCUSSION
The deletions that are shown schematically in 
Figure 1 are all expected to result in an absent or a 
nonfunctional REP-1 gene product. Not surpris­
ingly there is no obvious conelation between the 
size or the breakpoints of the deletions and the 
clinical manifestation of choroideremia in these 
patients.
The two female patients carrying balanced X-au- 
tosome translocations that involve the REP-1 gene 
(Fig. 1) show a mild disease course. Usually, in
females with reciprocal X-autosomal translocations 
the normal X is preferentially inactivated while 
both translocation fragments remain active. How­
ever, there is evidence that the REP-1 gene partly 
escapes X-chromosome inactivation (Carrel and
Willard, 1993; T.J.R.v.d. Pol and J.A.J.M.v.d.
Hurk, unpublished observations). The presence of 
a low level of functional REP-1 transcript could 
account for the mild manifestation of choroidere- 
mia in these female patients.
Point mutations and small insertions/deletions 
have been found in exons 5-14  of the REP-l gene 
(Table 1). Recombinant REP-1 protein that lacks 
the 49 C-terminal amino acids is still able to assist 
in the geranylgeranylation of Rab proteins (F.P.M. 
Cremers and M. Seabra, unpublished observa­
tions), indicating that mutations in exon 15 may 
not cause CHM. The reason for the absence of 
subtle mutations in exons 1—4 is unclear.
The majority (70%) of small alterations in the 
REP-1 gene are nonsense and frameshift mutations 
that result in premature translation termination 
codons (Table 1). In many instances, the primary 
consequence of a premature stop codon is severe or 
complete loss of mRNA from the mutant allele. A  
normal level may be retained if the inappropriate 
termination codon occurs toward the 3 ' end of the 
transcript (McIntosh et al., 1993). If any protein is 
produced from the mutant allele it will be trun­
cated at the C-terminus. Recently, it has been 
shown that recombinant REP-1 protein that lacks 
the 70 C-terminal amino acids is unable to func­
tion as a subunit of Rab GGTase (F.P.M. Cremers 
and M. Seabra, unpublished observations). Since 
the aforementioned nonsense and frameshift mu­
tations in the REP-1 gene predict C-terminal trun­
cations of more than 70 amino acids, it is clear that
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t a b l e  2. Polymorphisms in the REP-1 Gene
Location Polymorphism Heterozygosity References
Exon 5 381 G/A 0.40 This study
Intron 8 pZlla-EcoRV 0.50 Molloy et aL, 1992
pZlla-MspI 0.43
pZllc-£coRI 0.46
Intron 9 (ATJs.fiAC repeat 0.87 Van Bokhoven et al., 1996
Intron 14 (CA)19 repeat 0.67 Van Bokhoven et al., 1994d
any resulting REP-1 proteins will be nonfunc­
tional.
The remaining 30% of small alterations in the 
REP-1 gene are mutations that affect splice sites 
(Table 1). In family M, the A—>T change at po­
sition 1442 not only alters the 5' splice site in exon
11 but also predicts a glutamine to leucine substi­
tution. The effect of the point mutation has not 
been determined directly, yet Western blot analy­
sis failed to detect any REP-1 protein in EBV trans­
formed lymphoblasts of a patient from this family 
(M. Seabra and O. Pascal, personal communica- 
tion). Although it cannot be excluded that an 
amino acid substitution generates a highly unstable 
protein, it is more likely that the A-»T change 
affects RN A  splicing or, since only one third of the 
coding region was screened, that there is another 
mutation in the REP-1 gene in this family. Further 
studies are required to establish the status and ef­
fect of the A—»T change. Three splice site muta­
tions listed in Table 1 have been characterized at 
the transcript level. One of these (P21.420) results 
in a mixture of in-frame and frameshifted mRNAs 
(T.J.R.v.d. Pol and J.A.J.M.v.d. Hurk, unpub­
lished observations). The other two splice site mu­
tations (FC and CHM*Sal) lead to aberrantly 
spliced transcripts containing premature termina­
tion codons that predict C-terminal protein trun­
cations of more than 70 amino acids (M. Schwartz, 
unpublished observations; Sankila et al., 1992).
The (vast majority of) subtle mutations ap­
peals) to completely inactivate the REP-1 gene 
product. This finding explains why there is no ap­
parent correlation between the clinical severity of 
the disorder and the underlying mutations. The 
striking absence of missense mutations may indi­
cate that these have no clinical effect. However, 
this would imply a low pressure on sequence con­
servation, which is contradicted by the high degree 
of homology between the human, rat, and mouse 
sequences, and by the fact that only one polymor­
phism was ever found in the protein coding region 
of the human REP-1 gene. A more likely possibil­
ity would be that missense mutations give rise to a
different disease phenotype. Alternatively, they 
may be lethal because of interference with the 
function of the REP-2 gene product; for example, 
the resulting REP-1 proteins may be able to irre­
versibly bind the a/p catalytic component of Rab
GGTase.
The spectrum of REP-1 gene defects described 
here enables the definition of the most efficient 
strategy for future mutation screening. So far, de­
tection of REP-1 mutations has largely been per­
formed on genomic DNA, In view of the frequent 
occurrence of gross rearrangements, a preliminary 
screen for (partial) REP-1 deletions by polymerase 
chain reaction (PCR) amplification of exons 1, 8, 
and 15 would be a logical first step in mutation 
detection. Subsequently, all exons and adjacent 
intronic sequences could be PCR-ampIified from 
genomic DNA and scanned for small alterations 
using single-strand conformation analysis (Orita et 
al,, 1989) or heteroduplex analysis (White et a l,  
1992). Both methods are attractive because of 
their technical simplicity and relative sensitivity 
(Perry et al., 1992; White et al., 1992; Sheffield et 
al., 1993). Alternatively, mutation analysis could 
be carried out on mRNA derived from lympho­
blasts. This might be a more practical starting ma­
terial since larger stretches of coding sequences can 
be screened, and the effect of the mutation on 
transcript structure can be readily observed. The
first step in mRNA analysis, RT-PCR (Fig. 2),
detects gross rearrangements and mutations that 
affect splicing. More subtle mutations in the RT- 
PCR products can be detected by chemical mis­
match cleavage (Cotton et al., 1988) or protein 
truncation tests (PTT) (Roest et ah, 1993). The 
latter method specifically detects translation ter­
mination mutations. Since virtually all nondele­
tion CHM cases analyzed so far are small mutations 
that introduce premature termination codons, 
PTT might be the method of choice for REP-1 
mutation screening.
In approximately one-third of European CHM 
patients screened for defects in the REP-1 protein 
coding region, the causative mutation has not
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been identified. It should he .stressed that this is 
generally not a problem for genetic counseling be­
cause in most (familial) cases intragenic polymor­
phisms (Table 2), in particular the two highly 
polymorphic microsatellites, enable accurate pre- 
symptomatic diagnosis and carrier detection. How­
ever, in sporadic Cl livl cases in which the diagno­
sis is less certain, mutation detection remains
inevitable*
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